Literature DB >> 15118854

Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies.

Tina Dreher1, Hanswalter Zentgraf, Ulrich Abel, Alexandra Kappeler, Maurice S Michel, Uwe Bleyl, Rainer Grobholz.   

Abstract

The extreme variability of prostate cancer implies latent disease with missing clinical symptoms in some cases. Tumor suppressors PTEN (phosphatase and tensin homolog deleted on chromosome ten) and p27kip1 are frequently mutated in various human cancers. PTEN negatively influences cell growth and induces apoptosis, while p27kip1 binds to cyclin-E-Cdk2 and counteracts mitosis. This study investigated the expression of PTEN and p27kip1 in prostatectomies and needle biopsies in order to determine whether protein localization or expression levels are correlated with tumor grade and whether PTEN and p27kip1 expression in biopsies are valuable predictive tumor markers. Analysis of PTEN demonstrated that weak expression levels were significantly more prevalent in high-grade tumors. Analysis of p27kip1 revealed that high-grade tumors had a higher percentage of cytoplasmic localization of the protein than low-grade tumors, where nuclear localization was more frequent. Furthermore, this study indicated a positive association between PTEN and p27kip1 levels. An increase of high-grade tumors corresponded to a progressive loss of both tumor suppressors in needle biopsies and prostatectomies. p27kip1 and PTEN did not show a higher predictive accuracy of the tumor grade in the surgical specimen than the Gleason score. However, p27kip1 had the same predictive value as the Gleason score in needle biopsies. Copyright 2004 Springer-Verlag

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118854     DOI: 10.1007/s00428-004-1004-6

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  30 in total

1.  Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1).

Authors:  P F Dijkers; R H Medema; C Pals; L Banerji; N S Thomas; E W Lam; B M Burgering; J A Raaijmakers; J W Lammers; L Koenderman; P J Coffer
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Translational control of p27Kip1 accumulation during the cell cycle.

Authors:  L Hengst; S I Reed
Journal:  Science       Date:  1996-03-29       Impact factor: 47.728

Review 3.  Histologic grading of prostate cancer: a perspective.

Authors:  D F Gleason
Journal:  Hum Pathol       Date:  1992-03       Impact factor: 3.466

4.  Fas ligand expression in Hodgkin lymphoma.

Authors:  C S Verbeke; U Wenthe; R Grobholz; H Zentgraf
Journal:  Am J Surg Pathol       Date:  2001-03       Impact factor: 6.394

5.  Cancer statistics, 2002.

Authors:  Ahmedin Jemal; Andrea Thomas; Taylor Murray; Michael Thun
Journal:  CA Cancer J Clin       Date:  2002 Jan-Feb       Impact factor: 508.702

6.  Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.

Authors:  G L Mutter; M C Lin; J T Fitzgerald; J B Kum; J P Baak; J A Lees; L P Weng; C Eng
Journal:  J Natl Cancer Inst       Date:  2000-06-07       Impact factor: 13.506

7.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

8.  MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.

Authors:  D H Teng; R Hu; H Lin; T Davis; D Iliev; C Frye; B Swedlund; K L Hansen; V L Vinson; K L Gumpper; L Ellis; A El-Naggar; M Frazier; S Jasser; L A Langford; J Lee; G B Mills; M A Pershouse; R E Pollack; C Tornos; P Troncoso; W K Yung; G Fujii; A Berson; P A Steck
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

9.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.

Authors:  Incheol Shin; F Michael Yakes; Federico Rojo; Nah-Young Shin; Andrei V Bakin; Jose Baselga; Carlos L Arteaga
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

10.  Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer.

Authors:  Yongde Liao; Rainer Grobholz; Ulrich Abel; Lutz Trojan; Maurice Stephan Michel; Peter Angel; Doris Mayer
Journal:  Int J Cancer       Date:  2003-11-20       Impact factor: 7.396

View more
  23 in total

1.  A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.

Authors:  Andrew J Armstrong; George J Netto; Michelle A Rudek; Susan Halabi; David P Wood; Patricia A Creel; Kelly Mundy; S Lindsay Davis; Ting Wang; Roula Albadine; Luciana Schultz; Alan W Partin; Antonio Jimeno; Helen Fedor; Phillip G Febbo; Daniel J George; Robin Gurganus; Angelo M De Marzo; Michael A Carducci
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

Review 2.  Targeted approaches for the management of metastatic prostate cancer.

Authors:  Kathleen W Beekman; Maha Hussain
Journal:  Curr Oncol Rep       Date:  2006-05       Impact factor: 5.075

Review 3.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

4.  Effect of p27 gene combined with Pientzehuang ([characters: see text]) on tumor growth in osteosarcoma-bearing nude mice.

Authors:  Shou-song Ren; Fang Yuan; Ying-hong Liu; Le-tian Zhou; Jun Li
Journal:  Chin J Integr Med       Date:  2014-08-20       Impact factor: 1.978

5.  Vitamin K2, a menaquinone present in dairy products targets castration-resistant prostate cancer cell-line by activating apoptosis signaling.

Authors:  Subramanyam Dasari; Angela Lincy Prem Antony Samy; Andre Kajdacsy-Balla; Maarten C Bosland; Gnanasekar Munirathinam
Journal:  Food Chem Toxicol       Date:  2018-02-09       Impact factor: 6.023

6.  Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer.

Authors:  Alcides Chaux; Sarah B Peskoe; Nilda Gonzalez-Roibon; Luciana Schultz; Roula Albadine; Jessica Hicks; Angelo M De Marzo; Elizabeth A Platz; George J Netto
Journal:  Mod Pathol       Date:  2012-06-08       Impact factor: 7.842

Review 7.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Todd M Morgan; Theodore D Koreckij; Eva Corey
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

Review 8.  PTEN function: how normal cells control it and tumour cells lose it.

Authors:  Nick R Leslie; C Peter Downes
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

Review 9.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

Authors:  Jaclyn LoPiccolo; Gideon M Blumenthal; Wendy B Bernstein; Phillip A Dennis
Journal:  Drug Resist Updat       Date:  2007-12-31       Impact factor: 18.500

10.  RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid.

Authors:  Todd M Morgan; Tiffany E M Pitts; Ted S Gross; Sandra L Poliachik; Robert L Vessella; Eva Corey
Journal:  Prostate       Date:  2008-06-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.